<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02410122</url>
  </required_header>
  <id_info>
    <org_study_id>NA_00092688</org_study_id>
    <nct_id>NCT02410122</nct_id>
  </id_info>
  <brief_title>The Natural History of the Progression of Atrophy Secondary to Stargardt Disease Type 4: PROM1-Related Macular Dystrophy</brief_title>
  <acronym>ProgStar-4</acronym>
  <official_title>The Natural History of the Progression of Atrophy Secondary to Stargardt Disease Type 4 (STGD4): A Prospective Longitudinal Observational Study of Stargardt Disease Type 4, a PROM1- Related Macular Dystrophy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Shulsky Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Johns Hopkins University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      While a fair amount of clinical data on Stargardt disease type 1 (STGD1) have been published,
      very little is known about Stargardt disease type 4 (STGD4). The ProgStar 04 study is an
      important opportunity to leverage the infrastructure, clinical trials sites, methods, and
      central reading center of the ProgStar program to investigate the progression of STGD4 and
      will help to establish patient cohorts worldwide for future clinical trials.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The PROM1 gene codes a protein called Prominin 1 (PROM1; also known as CD133 and AC133), most
      known for its original use as a human stem cell-specific marker. In the retina, PROM1 is
      involved in the formation and organization of disks within the outer segment (OS) of the
      photoreceptors. It is within this particular region that most of the electrochemical signals
      in response to light are generated (visual cycle-phototransduction). In STGD4, mutations in
      the PROM1 gene result in a defective isoform of the PROM1 protein that becomes trapped in the
      myoid region of the photoreceptors and cannot migrate to the OS site where disks are formed.
      Ultimately, the absence of PROM1 in the OS affects the growth and organization of the disks,
      which leads to disk malfunction and to vision problems.

      Although many advances in genetic science have helped to recognize this variant of STGD, a
      comprehensive description of the natural history, including the variability in cone and rod
      dysfunction, of this STGD variant is not available. While there is no known treatment for
      STGD at this time, the preparation for future therapeutic approaches and for planning
      clinical trials must include an understanding of the disease itself, its variability, its
      progression and its correlation with visual loss. Moreover, clinical trials that aim to slow
      down the progression and/or to restore vision require validated outcome measures to prove
      treatment efficacy. However, such outcomes have not been established for STGD overall.

      In summary, the characterization of STGD4-specific clinical manifestations, progression and
      prognosis as well as identification of outcome measures for clinical trials are critical to
      develop new clinical trials for STGD4. Hence, ProgStar 4 is developed as a prospective
      longitudinal observational study of patients with mutations in the PROM1 gene and a phenotype
      consistent with STGD.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>December 2014</start_date>
  <completion_date type="Anticipated">March 2018</completion_date>
  <primary_completion_date type="Anticipated">March 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Growth of atrophic lesions as measured by fundus autofluorescence (FAF) imaging</measure>
    <time_frame>24 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Growth of atrophic lesions as measured by fundus autofluorescence (FAF) imaging</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of retinal thinning and photoreceptor loss as measured by spectral domain optical coherence tomography (sd-OCT)</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of retinal thinning and photoreceptor loss as measured by spectral domain optical coherence tomography (sd-OCT)</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Loss of retinal sensitivity as measured by microperimetry</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Loss of retinal sensitivity as measured by microperimetry</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in best-corrected visual acuity by using the Early Treatment Diabetic Retinopathy Study (ETDRS) protocol</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in best-corrected visual acuity by using the Early Treatment Diabetic Retinopathy Study (ETDRS) protocol</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of all outcome measures with genetic profile</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of all outcome measures with genetic profile</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">15</enrollment>
  <condition>Stargardt Disease</condition>
  <eligibility>
    <study_pop>
      <textblock>
        The study shall enroll participants with PROM1 mutations and associated STGD4 phenotype at
        up to 10 clinical sites.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Provide a signed informed consent form and authorization allowing the disclosure and
             use of protected health information.

          2. The designated primary study eye must have at least one well-demarcated area of
             atrophy. The lesion size should not exceed the area to be tracked in the OCT mode
             (20x20 degrees).

          3. Have at least one pathogenic mutation confirmed in the PROM1 gene and a Stargardt
             phenotype.

          4. The primary study eye must have clear ocular media and adequate pupillary dilation to
             permit good quality FAF and sd-OCT imaging in the opinion of the investigator.

          5. Be able to cooperate in performing the examinations.

          6. Be willing to undergo ocular examinations once every 6 months for up to 24 months.

          7. Be at least six years old.

          8. Both eyes can be included if inclusion criteria are fulfilled for both eyes.

        Exclusion Criteria:

          1. Ocular disease, such as choroidal neovascularization, glaucoma and diabetic
             retinopathy, in either eye that may confound assessment of the retina morphologically
             and functionally.

          2. Intraocular surgery in the primary study eye within 90 days prior to baseline visit.

          3. Current or previous participation in an interventional study to treat STGD such as
             gene therapy or stem cell therapy. Current participation in a drug trial or previous
             participation in a drug trial within six months before enrollment. The use of oral
             supplements of vitamins and minerals are permitted although the current use of Vitamin
             A supplementation shall be documented.

          4. The site Principal Investigator may declare any patient at their site ineligible to
             participate in the study for a sound medical reason prior to the patient's enrollment
             into the study.

          5. Any systemic disease with a limited survival prognosis (e.g. cancer, severe/unstable
             cardiovascular disease).

          6. Any condition that would make adherence to the examination interfere with the patient
             attending their regular follow-up visits schedule of once every 6 months for up to 24
             months difficult or unlikely, e.g. personality disorder, use of major tranquilizers
             such as Haldol or Phenothiazine, chronic alcoholism, Alzheimer's Disease or drug
             abuse.

          7. Evidence of significant uncontrolled concomitant diseases such as cardiovascular,
             neurological, pulmonary, renal, hepatic, endocrine or gastro-intestinal disorders.

          8. Patient is known to have one or more pathogenic mutation(s) in the ABCA4, RDS, or
             ELOVL4 genes.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hendrik P Scholl, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Wilmer Eye Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Wilmer Eye Institute</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retina Foundation of the Southwest</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universit√§ts-Augenklinik Bonn</name>
      <address>
        <city>Bonn</city>
        <zip>53127</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Opthalmic Research, University of Tuebingen</name>
      <address>
        <city>Tuebingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Moorfields Eye Hospital</name>
      <address>
        <city>London</city>
        <zip>EC1V 2PD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Switzerland</country>
  </removed_countries>
  <link>
    <url>http://progstar.org/progstar-home/progstar-4/</url>
    <description>Click here for more information about this study: the Natural History of the Progression of Atrophy Secondary to Stargardt Disease (ProgStar)</description>
  </link>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 5, 2015</study_first_submitted>
  <study_first_submitted_qc>April 1, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 7, 2015</study_first_posted>
  <last_update_submitted>December 5, 2017</last_update_submitted>
  <last_update_submitted_qc>December 5, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrophy</mesh_term>
    <mesh_term>Macular Degeneration</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

